Paragon's Mentari hits Nasdaq via reverse merger with $290M PIPE, Relay scores in vascular anomalies and tags a $175M raise, and Regeneron seeds a $2.3B Helicon bet at Parabilis.
Friday’s big three: an FDA gene-therapy approval with a “free in the U.S.” twist, a federal drug-cost agreement, and an AbbVie CRL tied to manufacturing.
Thursday: Dupixent pediatrics + the $9B Inhibrx bid-watch
Dupixent picked up a U.S. label in children aged 2–11 with uncontrolled chronic spontaneous urticaria, while Inhibrx’s oncology assets entered the bid-watch zone.
